Clinical significance of intratumoral HER2 heterogeneity in gastric cancer

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1448-1457

  Lee, Hee Eun ^a   Park, Kyoung Un ^b   Yoo, Seol Bong ^c   Nam, Soo Kyung ^b   Park, Do Joong ^b   Kim, Hyung Ho ^b   Lee, Hye Seung ^b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Fluorescence in situ hybridisation; Gene amplification; HER2 gene; Immunohistochemistry; Intratumoral genetic heterogeneity; Stomach neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL TIME;

AGED; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 84875748656     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.10.018     Document Type: Article

References (30)

1. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137
2. Y. Madarnas, M. Trudeau, and J.A. Franek Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review Cancer Treat Rev 34 2008 539 557
3. C.L. Vogel, M.A. Cobleigh, and D. Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726
4. Y.J. Bang, E. Van Cutsem, and A. Feyereislova Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
5. C. Gravalos, and A. Jimeno HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 2008 1523 1529
6. M. Tanner, M. Hollmen, and T.T. Junttila Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 2005 273 278
7. C. Rebischung, R. Barnoud, and L. Stefani The effectiveness of trastuzumab (herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein Gastric Cancer 8 2005 249 252
8. Y. Matsui, M. Inomata, and M. Tojigamori Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model Int J Oncol 27 2005 681 685
9. K. Fujimoto-Ouchi, F. Sekiguchi, and H. Yasuno Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models Cancer Chemother Pharmacol 59 2007 795 805
10. European Medicines Agency. Opinion. < www.emea.europa.eu/pdfs/human/ opinion/Herceptin-82246709en.pdf >; 2009
11. A. Fabi, A. Di Benedetto, and G. Metro HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care Clin Cancer Res 17 2011 2055 2064
12. G. Somlo, C.L. Martel, and S.K. Lau A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer Breast Cancer Res Treat 131 2012 899 906
13. H. Seol, H.J. Lee, and Y. Choi Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 2012 938 948
14. M. Hofmann, O. Stoss, and D. Shi Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
15. M.A. Kim, E.J. Jung, and H.S. Lee Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction Hum Pathol 38 2007 1386 1393
16. J. Ruschoff, I. Nagelmeier, and G. Baretton Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe 31 2010 208 217
17. G.H. Vance, T.S. Barry, and K.J. Bloom Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines Arch Pathol Lab Med 133 2009 611 612
18. A.I. Bartlett, J. Starcyznski, and T. Robson Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition Am J Clin Pathol 136 2011 266 274
19. M.C. Chang, J.I. Malowany, J. Mazurkiewicz, and M. Wood 'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases Mod Pathol 25 2012 683 688
20. C. Fenoglio-Preiser, F. Carneiro, and P. Correa Gastric carcinoma S.R. Hamilton, L.A. Aaltonen, World Health Organization classification of tumors: pathology and genetics of tumors of the digestive system 2000 IARC Press Lyon 39 52
21. American Joint Committee on Cancer Chapter 11. Stomach S.B. Edge, D.R. Byrd, C.C. Campton, AJCC cancer staging manual 7th ed. 2009 Springer New York 117 126
22. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method Methods 25 2001 402 408
23. R. Kindich, A.R. Florl, and V. Jung Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer Clin Chem 51 2005 649 652
24. J. Ruschoff, M. Dietel, and G. Baretton HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing Virchows Arch 457 2010 299 307
25. J. Ruschoff, W. Hanna, and M. Bilous HER2 testing in gastric cancer: a practical approach Mod Pathol 25 2012 637 650
26. M. Brunelli, E. Manfrin, and G. Martignoni Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria Am J Clin Pathol 131 2009 678 682
27. J.T. Lewis, R.P. Ketterling, and K.C. Halling Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining Am J Clin Pathol 124 2005 273 281
28. J.M. Striebel, R. Bhargava, and C. Horbinski The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management Am J Clin Pathol 129 2008 383 390
29. C.B. Moeder, J.M. Giltnane, and M. Harigopal Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome J Clin Oncol 25 2007 5418 5425
30. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145